(Q51468986)

5 April 2018

title

Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes. (English)

1 reference

5 April 2018

1 reference

1 reference

7

Frampton C

1 reference

5 April 2018

author name string

Shand B

1

1 reference

5 April 2018

Scott R

2

1 reference

5 April 2018

Connolly S

3

1 reference

5 April 2018

Clarke R

4

1 reference

5 April 2018

Baker J

5

1 reference

5 April 2018

Elder P

6

1 reference

5 April 2018

Yeo J

8

1 reference

5 April 2018

publication date

1 July 2007

1 reference

5 April 2018

Diabetes, Obesity and Metabolism

published in

1 reference

5 April 2018

volume

9

1 reference

5 April 2018

issue

4

1 reference

5 April 2018

page(s)

540-547

1 reference

5 April 2018

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00635.X

Beta-cell rejuvenation with thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00635.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00635.X

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00635.X

The epidemiology of diabetes and its complications in New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00635.X

Polynesians: prone to obesity and Type 2 diabetes mellitus but not hyperinsulinaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00635.X

Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00635.X

The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00635.X

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00635.X

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00635.X

Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00635.X

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00635.X

Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00635.X

10.1111/J.1463-1326.2006.00635.X

21 January 2018

Identifiers

DOI

1 reference

5 April 2018

1 reference

5 April 2018